CRISPR? That was so last year: Introducing the Bridge recombinase mechanism
Louise Martin reports on the novel genetic editing technique, the bridge recombinase mechanism, which may outshine CRISPR.
cancer
Continue reading
Guardians turned adversaries – the paradox of cancer immunity
Waywen Loh discusses how the immune system can fight cancer and where it fails and explores how immunity can be leveraged to treat cancer.
IP landmark cases: Yeda v. Rorer
In the last instalment of the IP landmark cases series, Emanuel Bor reflects on a case which determined the definition of inventorship.
Radiation: A journey to the Moon
Ben Bradley, Joshua Selfridge, and Siobann Bouyer report on the risk of space radiation and the potential risk of cosmic rays and how to mitigate these risks.
Vann: a virtual community against cancer
reports on a new app called Vann which aims to create a community among cancer patients as well as providing treatment tips.
The little-known risk of cosmic radiation in air travel
Olivia Allen and Enis Gerxhalija discuss cosmic radiation exposure as an occupational risk faced by cabin crew.
Peto’s Paradox: Insights into cancer through elephants, naked mole rats, and the Animal Kingdom
Isabel Schmidt discusses why larger animals do not show an increased cancer rate that is expected given their size.
The unexpected guest
Connor Forsyth discusses the recent explorations into the lung microbiome, and its role in treatment for cancer.
PROTACs: Targeting breakdown of specific proteins to treat diseases
Felicites Rapon explores the advantages of PROTACs over small molecule inhibitors in addressing cancer treatment and drug resistance.
The legacy of a girl who inspired a “holy grail” cancer-killing pill
Niamh Walker reports on the recent development of AOH1996, a pill targeting cancerous cells, offering a new approach to cancer treatment.
- 1
- 2